T-MAXIMUM’s B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer

RSS excerpt

BEIJING, Oct. 12, 2026 /PRNewswire/ — T-MAXIMUM PHARMACEUTICAL (“T-MAXIMUM”) today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T therapy, for the…